A Phase 3 interventional study of Adalimumab and Methotrexate in Early Rheumatoid Arthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 123 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-12.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 9th largest by enrollment, is one of 4 that started in 2000, is one of 36 in phase 3, and was the 2nd registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 4 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 799 is above the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
80 studies in Arthritis, Rheumatoid by AbbVie: 5 open now, 6 under way, 1 of them phase 3. Of 71 finished, 54 (76%) have results posted.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 3rd largest by enrollment of the 38 interventional ones that give a count, is the only one that started in 2000, is one of 11 in phase 3, and was the 2nd registered.
AbbVie’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 80 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the safety and efficacy of adalimumab in combination with methotrexate in patients with recent onset rheumatoid arthritis (RA), and to assess the long-term safety and maintenance of efficacy after treatment with adalimumab for up to 10 years.
This study had an initial 2-year double-blind treatment period followed by an 8-year open-label extension period, for a total of up to 10 years study duration. The study was designed to assess the potential of adalimumab + methotrexate to improve signs and symptoms of disease and to inhibit radiographic progression in patients with recent onset (disease duration less than 3 years) rheumatoid arthritis not previously treated with methotrexate. Adalimumab is a human anti-tumor necrosis factor (TNF) monoclonal antibody.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase and then adalimumab 40 mg every other week for up to 8 years in the open-label extension.
Biological: Adalimumab · Drug: Methotrexate placebo
Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.
Biological: Adalimumab · Drug: Methotrexate
Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.
Drug: Methotrexate · Biological: Adalimumab placebo
Also known as: ABT-D2E7, Humira
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 52
American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); * Acute phase reactant value (C-Reactive Protein). Participants who withdrew early were considered non-responders.
Time frame: Baseline and 52 Weeks
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52
The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and Week 52 were scored in a blinded manner. Joints were scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
Time frame: Baseline and Week 52
Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.
Time frame: Baseline and Week 52
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 104
American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were considered non-responders.
Time frame: Baseline and Week 104
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 104
The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and Week 104 were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
Time frame: Baseline and Week 104
Number of Participants Who Achieved Clinical Remission, Defined as a Disease Activity 28 (DAS28) Score < 2.6 at Week 52
The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C reactive protein, and general health were included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.
Time frame: Week 52
Change From Baseline in the Physical Component of the Short Form-36 Health Status Survey (SF-36) at Week 52
The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.
Time frame: Baseline and Week 52
Number of Participants With Major Clinical Response After 104 Weeks of Treatment
Major clinical response was defined as an American College of Rheumatology 70% (ACR70) response for any six continuous months, over 104 weeks of treatment. A participant was a responder if the following criteria for improvement from Baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were non-responders.
Time frame: Any 6 continuous months from Baseline to Week 104
Change From Baseline in the Mental Component of the Short Form-36 Health Status Survey (SF-36) at Week 52
The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.
Time frame: Baseline and Week 52
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Weeks 26 and 76
American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were considered non-responders.
Time frame: Baseline and Weeks 26 and 76
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria During the Double-blind Phase
American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were considered non-responders.
Time frame: Baseline and Weeks 26, 52, 76, and 104
Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria During the Double-blind Phase
American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were considered non-responders.
Time frame: Baseline and Weeks 26, 52, 76, and 104
Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) During the Double-blind Treatment Phase
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.
Time frame: Baseline and Weeks 12, 26, 76, and 104
Number of Participants With Improvement in the HAQ-DI Score ≥ 0.3 During the Double-blind Treatment Phase
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability.
Time frame: Baseline and Weeks 26, 52, 76, and 104
Change From Baseline in Health Utilities Index Mark 2 and Mark 3 (HUI 2/3) During the Double-blind Treatment Phase
The HUI 2/3 is an assessment of various aspects of participants' health and ability to perform various tasks on a day-to-day basis, including reading, seeing, hearing, speaking, general outlook on life, pain/discomfort, ability to walk, use of hands, memory, ability to think/solve, and ability to perform basic activities such as eating, bathing, and dressing. The HUI 2/3 is a combined 15-item questionnaire based on a recall period of the previous 4 weeks. HUI-2 and HUI-3 scores are calculated independently. The HUI-2 score includes 6 attributes: Sensation, Mobility, Emotion, Cognition, Self-Care, and Pain. The HUI-3 score is comprised of 8 attributes: Vision, Hearing, Speech, Ambulation, Dexterity, Emotion, Cognition, and Pain. The range of each score is from 0 (dead) to 1 (perfect health). An increase from Baseline indicates improvement.
Time frame: Baseline and Weeks 26, 52, and 104
Change From Baseline in the Short Form-36 Health Status Survey (SF-36) During the Double-blind Treatment Phase
The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component and items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.
Time frame: Baseline and Weeks 26 and 104
Numeric American College of Rheumatology (ACR-N) During the Double-blind Treatment Phase
ACR-N is a composite, continuous variable which measures the percentage of improvement from Baseline in individual participants based on the 7 core set variables of the ACR. ACR-N is defined as the smallest percent change from Baseline of 3 measures: tender joint counts (TJC), swollen joint counts (SJC), and the median percent improvement in the 5 remaining measures (Patient's Assessment of Pain, Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Health Assessment Questionnaire - Disability Index \[HAQ-DI\], and C-Reactive Protein). A positive ACR-N value indicates improvement; a negative ACR-N value indicates worsening; ACR-N of 0 indicates no change.
Time frame: Baseline and Weeks 26, 52, 76, and 104
Change From Baseline in Disease Activity Score (DAS28) During the Double-blind Treatment Phase
The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables: * 28 tender joint counts, * 28 swollen joint counts, * C-reactive protein, and * Patient's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.
Time frame: Baseline and Weeks 26, 52, 76, and 104
Change From Baseline in Joint Erosion Score During the Double-blind Treatment Period
Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints on each hand/wrist (17 joints) and each forefoot (6 joints) were scored for erosions on a scale of 0 = no erosions; 1 = 1 discrete erosion or ≤20% joint involvement; 2 = 2 separate quadrants with erosion or 21-40% joint involvement; 3 = 3 separate quadrants with erosion or 41-60% joint involvement; 4 = all 4 quadrants with erosion or 61-80% joint involvement; and 5 = extensive destruction with \>80% joint involvement. Scores were summed to calculate the total erosion score, which ranges from 0 (no erosion)to 230 (worst). A large increase in erosion score is indicative of worsening, whereas a small change or no change is indicative of inhibition of joint erosion.
Time frame: Baseline and Weeks 52 and 104
Change From Baseline in Joint Space Narrowing Score During the Double-blind Treatment Period
Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joint space narrowing (JSN) scores were recorded for each hand/wrist (16 joints) and each forefoot (5 joints) on a 5-point scale (0 = no narrowing; 1 = up to 25% narrowing; 2 = 26-65% narrowing; 3 = 66-99% narrowing; and 4 = complete narrowing). Scores were summed to calculate the total score ranging from 0 (no narrowing) to 168 (maximum narrowing). A large increase in joint narrowing score is indicative of worsening, whereas a small change or no change is indicative of inhibition of JSN.
Time frame: Baseline and Weeks 52 and 104
Number of Participants With No Worsening in Modified Total Sharp Score or Components During the Double-blind Treatment Phase
The number of participants with no worsening in the modified Total Sharp Score (mTSS) and in erosion and joint space narrowing (JSN) scores, where no worsening is defined as a change from Baseline of ≤ 0 in mTSS, erosion score and JSN score, at Weeks 52 and 104. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
Time frame: Baseline and Weeks 52 and 104
Number of Participants With No Erosions at Baseline and No New Erosions at Weeks 52 and 104
The number of participants with no erosions at Baseline and no erosions at Weeks 52 and 104, where no erosions and no new erosions are defined as an erosion score = 0. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints on each hand/wrist (17 joints) and each forefoot (6 joints) were scored for erosions on a scale of 0 = no erosions; 1 = 1 discrete erosion or ≤20% joint involvement; 2 = 2 separate quadrants with erosion or 21-40% joint involvement; 3 = 3 separate quadrants with erosion or 41-60% joint involvement; 4 = all 4 quadrants with erosion or 61-80% joint involvement; and 5 = extensive destruction with \>80% joint involvement. Scores were summed to calculate the total erosion score, which ranges from 0 (no erosion) to 230 (worst).
Time frame: Baseline and Weeks 52 and 104
Number of Participants With Non-Involved Joints at Baseline and No Newly Involved Joints at Weeks 52 and 104
Number of participants with non-involved joints at Baseline and no newly involved joints at Weeks 52 and 104, where involved joints or no newly involved joints are defined as modified Total Sharp Score (mTSS) = 0. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]).
Time frame: Baseline and Weeks 52 and 104
Number of Participants Meeting ACR20 Response Criteria Over 10 Years by Adalimumab Exposure
American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Baseline is the last value prior to the first dose of adalimumab. For participants randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.
Time frame: Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.
Number of Participants Meeting ACR50 Response Criteria Over 10 Years by Adalimumab Exposure
American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Baseline is the last value prior to the first dose of adalimumab. For patients randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.
Time frame: Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.
Number of Participants Meeting ACR70 Response Criteria Over 10 Years by Adalimumab Exposure
American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Baseline is the last value prior to the first dose of adalimumab. For patients randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.
Time frame: Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.
Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) Over 10 Years by Adalimumab Exposure
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.
Time frame: Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.
Change From Baseline in DAS28 Over 10 Years by Adalimumab Exposure
The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables: * 28 tender joint counts, * 28 swollen joint counts, * C-reactive protein, and * Patient's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.
Time frame: Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.
Number of Participants With DAS28 < 2.6 and < 3.2 Over 10 Years by Adalimumab Exposure
The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables: * 28 tender joint counts, * 28 swollen joint counts, * C-reactive protein, and * Patient's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.
Time frame: After 1, 2, 5, and 10 years of adalimumab exposure
Change From Baseline in Modified Total Sharp Score (mTSS) Over 10 Years
The modified TSS (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
Time frame: Baseline (prior to first study drug treatment) and Years 2 and 10
Number of Participants With No Radiographic Progression Over 10 Years
The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement. The number of participants with change from Baseline ≤ 0.5 and ≤ 0 is reported as a measure of no disease progression.
Time frame: Baseline (prior to first study drug treatment) and Years 2 and 10.
Composite Score of ACR50 Plus No Change in Modified Total Sharp Score
Time frame: Year 10
Number of Participants With a Major Clinical Response Over 10 Years by Adalimumab Exposure
A major clinical response was defined as maintenance of an ACR70 response for at least a 6-month continuous period at any time during the study following the first dose of adalimumab. A participant was a responder if the following criteria for improvement from Baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein).
Time frame: From the first dose of adalimumab (at Week 1 or Week 106 for patients initially randomized to methotrexate in the DB phase) to Year 10
Number of Participants With Improvement in HAQ-DI by 0.22 and 0.5 Units Over 10 Years by Adalimumab Exposure
The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A decrease in the HAQ-DI score represents an improvement in physical function; a clinically significant improvement is defined as a decrease of least 0.22 from Baseline in the HAQ-DI score. The number of participants with improvement in HAQ-DI of at least 0.22 and 0.5 units from Baseline is reported.
Time frame: Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.
Patients were enrolled at 94 sites in 15 countries between January 2001 and April 2004.
| Milestone | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Started | 257 | 274 | 268 |
| Completed | 164 | 166 | 196 |
| Not completed | 93 | 108 | 72 |
| Withdrew: Adverse event | 21 | 27 | 32 |
| Withdrew: Death | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 15 | 18 | 12 |
| Withdrew: Lack of efficacy | 47 | 52 | 13 |
| Withdrew: Protocol violation | 6 | 6 | 4 |
| Withdrew: Planned selection criteria | 0 | 1 | 0 |
| Withdrew: Recovery | 1 | 0 | 1 |
| Withdrew: Administrative reasons | 3 | 2 | 9 |
| Milestone | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Started | 155 | 159 | 183 |
| Completed | 79 | 85 | 86 |
| Not completed | 76 | 74 | 97 |
| Withdrew: Adverse event | 21 | 32 | 36 |
| Withdrew: Lost to follow-up | 9 | 2 | 6 |
| Withdrew: Recovery | 0 | 2 | 2 |
| Withdrew: Protocol violation | 3 | 4 | 4 |
| Withdrew: Death | 2 | 2 | 2 |
| Withdrew: Withdrawal by subject | 16 | 15 | 22 |
| Withdrew: Lack of efficacy | 14 | 6 | 12 |
| Withdrew: Administrative reasons | 11 | 11 | 13 |
American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); * Acute phase reactant value (C-Reactive Protein). Participants who withdrew early were considered non-responders.
| participants | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 52 | 118 | 113 | 165 |
The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and Week 52 were scored in a blinded manner. Joints were scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
| units on a scale | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52 | 5.7 ± 12.7 | 3.0 ± 11.2 | 1.3 ± 6.5 |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.
| units on a scale | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52 | -0.8 ± 0.6 | -0.8 ± 0.7 | -1.1 ± 0.6 |
American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were considered non-responders.
| participants | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 104 | 110 | 101 | 158 |
The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and Week 104 were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
| units on a scale | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Change From Baseline in Modified Total Sharp Score (mTSS) at Week 104 | 10.4 ± 21.7 | 5.5 ± 15.8 | 1.9 ± 8.3 |
The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C reactive protein, and general health were included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.
| participants | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Number of Participants Who Achieved Clinical Remission, Defined as a Disease Activity 28 (DAS28) Score < 2.6 at Week 52 | 53 | 64 | 115 |
The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.
| units on a scale | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Change From Baseline in the Physical Component of the Short Form-36 Health Status Survey (SF-36) at Week 52 | 12.5 ± 9.6 | 12.6 ± 10.0 | 16.7 ± 10.2 |
Major clinical response was defined as an American College of Rheumatology 70% (ACR70) response for any six continuous months, over 104 weeks of treatment. A participant was a responder if the following criteria for improvement from Baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were non-responders.
| participants | Methotrexate Weekly | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Number of Participants With Major Clinical Response After 104 Weeks of Treatment | 70 | 67 | 130 |
The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.
| units on a scale | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Change From Baseline in the Mental Component of the Short Form-36 Health Status Survey (SF-36) at Week 52 | 6.5 ± 11.0 | 7.1 ± 12.3 | 7.2 ± 13.1 |
American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were considered non-responders.
| participants | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 26 | 104 | 96 | 157 |
| Week 76 | 114 | 114 | 161 |
American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were considered non-responders.
| participants | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 26 | 158 | 146 | 184 |
| Week 52 | 161 | 149 | 195 |
| Week 76 | 154 | 137 | 185 |
| Week 104 | 144 | 135 | 186 |
American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were considered non-responders.
| participants | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 26 | 57 | 54 | 114 |
| Week 52 | 70 | 71 | 122 |
| Week 76 | 75 | 79 | 127 |
| Week 104 | 73 | 77 | 125 |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.
| units on a scale | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 12 [N=236, 246, 252] | -0.6 ± 0.6 | -0.6 ± 0.6 | -0.8 ± 0.6 |
| Week 26 [N=217, 222, 240] | -0.8 ± 0.6 | -0.8 ± 0.7 | -0.9 ± 0.6 |
| Week 76 [N= 176, 175, 207] | -0.8 ± 0.6 | -0.9 ± 0.7 | -1.0 ± 0.7 |
| Week 104 [166, 162, 201] | -0.9 ± 0.6 | -0.9 ± 0.6 | -1.0 ± 0.7 |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability.
| participants | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 26 | 172 | 169 | 200 |
| Week 52 | 158 | 151 | 186 |
| Week 76 | 144 | 145 | 173 |
| Week 104 | 137 | 132 | 171 |
The HUI 2/3 is an assessment of various aspects of participants' health and ability to perform various tasks on a day-to-day basis, including reading, seeing, hearing, speaking, general outlook on life, pain/discomfort, ability to walk, use of hands, memory, ability to think/solve, and ability to perform basic activities such as eating, bathing, and dressing. The HUI 2/3 is a combined 15-item questionnaire based on a recall period of the previous 4 weeks. HUI-2 and HUI-3 scores are calculated independently. The HUI-2 score includes 6 attributes: Sensation, Mobility, Emotion, Cognition, Self-Care, and Pain. The HUI-3 score is comprised of 8 attributes: Vision, Hearing, Speech, Ambulation, Dexterity, Emotion, Cognition, and Pain. The range of each score is from 0 (dead) to 1 (perfect health). An increase from Baseline indicates improvement.
| units on a scale | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| HUI-2: Week 26 [N=192, 187, 205] | 0.2 ± 0.2 | 0.2 ± 0.2 | 0.2 ± 0.2 |
| HUI-2: Week 52 [N=179, 162, 189] | 0.2 ± 0.2 | 0.2 ± 0.2 | 0.2 ± 0.2 |
| HUI-2: Week 104 [N=152, 136, 174] | 0.2 ± 0.2 | 0.2 ± 0.2 | 0.2 ± 0.2 |
| HUI-3: Week 26 [N=192, 189, 205] | 0.3 ± 0.3 | 0.3 ± 0.3 | 0.3 ± 0.3 |
| HUI-3: Week 52 [N=177, 164, 190] | 0.3 ± 0.3 | 0.3 ± 0.3 | 0.4 ± 0.3 |
| HUI-3: Week 104 [N=154, 138, 177] | 0.3 ± 0.2 | 0.4 ± 0.3 | 0.4 ± 0.3 |
The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component and items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.
| units on a scale | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Physical Component: Week 26 [N=199, 204, 221] | 11.2 ± 10.0 | 10.8 ± 10.2 | 14.7 ± 10.2 |
| Physical Component: Week 104 [160, 157, 189] | 12.4 ± 10.3 | 13.4 ± 9.7 | 16.8 ± 11.2 |
| Mental Component: Week 26 [N=199, 204, 221] | 7.0 ± 11.6 | 5.2 ± 13.5 | 6.3 ± 12.1 |
| Mental Component: Week 104 [N=160, 157, 189] | 8.1 ± 10.9 | 6.6 ± 13.5 | 6.8 ± 12.0 |
ACR-N is a composite, continuous variable which measures the percentage of improvement from Baseline in individual participants based on the 7 core set variables of the ACR. ACR-N is defined as the smallest percent change from Baseline of 3 measures: tender joint counts (TJC), swollen joint counts (SJC), and the median percent improvement in the 5 remaining measures (Patient's Assessment of Pain, Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Health Assessment Questionnaire - Disability Index \[HAQ-DI\], and C-Reactive Protein). A positive ACR-N value indicates improvement; a negative ACR-N value indicates worsening; ACR-N of 0 indicates no change.
| percent change | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 26 [N=218, 224, 244] | 44.7 ± 42.2 | 39.1 ± 43.3 | 57.0 ± 42.2 |
| Week 52 [N=194, 193, 220] | 50.2 ± 48.2 | 44.4 ± 52.2 | 66.3 ± 34.8 |
| Week 76 [N=181, 179, 211] | 56.1 ± 38.1 | 51.5 ± 56.8 | 68.8 ± 31.3 |
| Week 104 [N=168, 167, 203] | 57.3 ± 37.1 | 54.0 ± 42.7 | 71.4 ± 31.0 |
The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables: * 28 tender joint counts, * 28 swollen joint counts, * C-reactive protein, and * Patient's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.
| units on a scale | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 26 [N=209, 218, 229] | -2.6 ± 1.3 | -2.4 ± 1.4 | -3.2 ± 1.3 |
| Week 52 [N=184, 185, 206] | -2.8 ± 1.4 | -2.8 ± 1.5 | -3.6 ± 1.3 |
| Week 76 [N=173, 173, 197] | -3.1 ± 1.2 | -3.0 ± 1.5 | -3.7 ± 1.3 |
| Week 104 [N=161, 158, 191] | -3.1 ± 1.4 | -3.2 ± 1.4 | -3.8 ± 1.3 |
Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints on each hand/wrist (17 joints) and each forefoot (6 joints) were scored for erosions on a scale of 0 = no erosions; 1 = 1 discrete erosion or ≤20% joint involvement; 2 = 2 separate quadrants with erosion or 21-40% joint involvement; 3 = 3 separate quadrants with erosion or 41-60% joint involvement; 4 = all 4 quadrants with erosion or 61-80% joint involvement; and 5 = extensive destruction with \>80% joint involvement. Scores were summed to calculate the total erosion score, which ranges from 0 (no erosion)to 230 (worst). A large increase in erosion score is indicative of worsening, whereas a small change or no change is indicative of inhibition of joint erosion.
| units on a scale | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 52 | 3.7 ± 8.4 | 1.7 ± 5.7 | 0.8 ± 3.3 |
| Week 104 | 6.4 ± 14.3 | 3.0 ± 8.3 | 1.0 ± 4.7 |
Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joint space narrowing (JSN) scores were recorded for each hand/wrist (16 joints) and each forefoot (5 joints) on a 5-point scale (0 = no narrowing; 1 = up to 25% narrowing; 2 = 26-65% narrowing; 3 = 66-99% narrowing; and 4 = complete narrowing). Scores were summed to calculate the total score ranging from 0 (no narrowing) to 168 (maximum narrowing). A large increase in joint narrowing score is indicative of worsening, whereas a small change or no change is indicative of inhibition of JSN.
| units on a scale | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 52 | 2.0 ± 6.3 | 1.3 ± 6.6 | 0.5 ± 4.2 |
| Week 104 | 4.0 ± 10.9 | 2.6 ± 9.5 | 0.9 ± 5.1 |
The number of participants with no worsening in the modified Total Sharp Score (mTSS) and in erosion and joint space narrowing (JSN) scores, where no worsening is defined as a change from Baseline of ≤ 0 in mTSS, erosion score and JSN score, at Weeks 52 and 104. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
| participants | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Modified Total Sharp Score: Week 52 | 78 | 112 | 141 |
| Modified Total Sharp Score: Week 104 | 70 | 105 | 136 |
| Erosion Scoe: Week 52 | 91 | 133 | 158 |
| Erosion Score: Week 104 | 81 | 121 | 148 |
| Joint Space Narrowing Score: Week 52 | 127 | 159 | 190 |
| Joint Space Narrowing Score: Week 104 | 112 | 147 | 175 |
The number of participants with no erosions at Baseline and no erosions at Weeks 52 and 104, where no erosions and no new erosions are defined as an erosion score = 0. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints on each hand/wrist (17 joints) and each forefoot (6 joints) were scored for erosions on a scale of 0 = no erosions; 1 = 1 discrete erosion or ≤20% joint involvement; 2 = 2 separate quadrants with erosion or 21-40% joint involvement; 3 = 3 separate quadrants with erosion or 41-60% joint involvement; 4 = all 4 quadrants with erosion or 61-80% joint involvement; and 5 = extensive destruction with \>80% joint involvement. Scores were summed to calculate the total erosion score, which ranges from 0 (no erosion) to 230 (worst).
| participants | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 52 | 8 | 10 | 13 |
| Week 104 | 7 | 8 | 11 |
Number of participants with non-involved joints at Baseline and no newly involved joints at Weeks 52 and 104, where involved joints or no newly involved joints are defined as modified Total Sharp Score (mTSS) = 0. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]).
| participants | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 52 | 4 | 9 | 12 |
| Week 104 | 3 | 7 | 9 |
American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Baseline is the last value prior to the first dose of adalimumab. For participants randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.
| participants | Any Adalimumab |
|---|---|
| Year 1 [N=410] | 340 |
| Year 2 [N=385] | 332 |
| Year 5 [N=325] | 231 |
| Year 10 [N=170] | 154 |
American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Baseline is the last value prior to the first dose of adalimumab. For patients randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.
| participants | Any Adalimumab |
|---|---|
| Year 1 [N=410] | 269 |
| Year 2 [N=385] | 266 |
| Year 5 [N=325] | 194 |
| Year 10 [N=170] | 127 |
American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Baseline is the last value prior to the first dose of adalimumab. For patients randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.
| participants | Any Adalimumab |
|---|---|
| Year 1 [N=410] | 186 |
| Year 2 [N=385] | 207 |
| Year 5 [N=325] | 153 |
| Year 10 [N=170] | 102 |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.
| units on a scale | Any Adalimumab |
|---|---|
| Year 1 [N=407] | -0.9 ± 0.68 |
| Year 2 [N=390] | -0.9 ± 0.70 |
| Year 5 [N=344] | -0.7 ± 0.73 |
| Year 10 [N=170] | -0.9 ± 0.73 |
The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables: * 28 tender joint counts, * 28 swollen joint counts, * C-reactive protein, and * Patient's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.
| units on a scale | Any Adalimumab |
|---|---|
| Year 1 [N=403] | -3.2 ± 1.49 |
| Year 2 [N=386] | -3.3 ± 1.61 |
| Year 5 [N=330] | -2.8 ± 1.93 |
| Year 10 [N=158] | -3.9 ± 1.29 |
The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables: * 28 tender joint counts, * 28 swollen joint counts, * C-reactive protein, and * Patient's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.
| participants | Adalimumab: DAS28 < 2.6 | Adalimumab: DAS28 < 3.2 |
|---|---|---|
| Year 1 [N=405] | 173 | 244 |
| Year 2 [N=389] | 215 | 271 |
| Year 5 [N=333] | 190 | 244 |
| Year 10 [N=159] | 109 | 135 |
The modified TSS (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.
| units on a scale | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Year 2 [N=83, 92, 89] | 6.3 ± 12.44 | 5.1 ± 9.63 | 0.3 ± 3.00 |
| Year 10 [N= 83, 93, 90] | 10.8 ± 20.01 | 9.2 ± 15.21 | 3.9 ± 9.64 |
The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement. The number of participants with change from Baseline ≤ 0.5 and ≤ 0 is reported as a measure of no disease progression.
| participants | Methotrexate | Adalimumab | Adalimumab + Methotrexate |
|---|---|---|---|
| Change ≤ 0.5 at Year 2 [N=83, 92, 89] | 36 | 40 | 65 |
| Change ≤ 0.5 at Year 10 [N=83, 93, 90] | 26 | 22 | 33 |
| Change ≤ 0 at Year 2 [N=83, 92, 89] | 22 | 30 | 51 |
| Change ≤ 0 at Year 10 [N=83, 93, 90] | 19 | 16 | 29 |
No measurements were reported for this outcome.
A major clinical response was defined as maintenance of an ACR70 response for at least a 6-month continuous period at any time during the study following the first dose of adalimumab. A participant was a responder if the following criteria for improvement from Baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein).
| participants | Any Adalimumab |
|---|---|
| Number of Participants With a Major Clinical Response Over 10 Years by Adalimumab Exposure | 273 |
The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A decrease in the HAQ-DI score represents an improvement in physical function; a clinically significant improvement is defined as a decrease of least 0.22 from Baseline in the HAQ-DI score. The number of participants with improvement in HAQ-DI of at least 0.22 and 0.5 units from Baseline is reported.
| participants | Adalimumab: HAQ Decrease ≥ 0.22 | Adalimumab: HAQ Decrease ≥ 0.5 |
|---|---|---|
| Year 1 [N=407] | 353 | 285 |
| Year 2 [N=390] | 324 | 265 |
| Year 5 [N=344] | 239 | 188 |
| Year 10 [N=170] | 140 | 112 |
Collected over For the double-blind treatment phase, up to 2 years (Methotrexate, Adalimumab and Adalimumab + Methotrexate reporting groups). For the Any Adalimumab reporting group, adverse events include the open-label extension, and are reported for up to 10 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Methotrexate | — | 47/257 (18.3%) | 227/257 (88.3%) |
| Adalimumab | — | 65/274 (23.7%) | 227/274 (82.8%) |
| Adalimumab + Methotrexate | — | 56/268 (20.9%) | 241/268 (89.9%) |
| Any Adalimumab | — | 320/697 (45.9%) | 634/697 (91%) |
| Event | Methotrexate | Adalimumab | Adalimumab + Methotrexate | Any Adalimumab |
|---|---|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 6/257 | 16/274 | 3/268 | 38/697 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/257 | 3/274 | 2/268 | 23/697 |
| PneumoniaInfections and infestations | 1/257 | 0/274 | 2/268 | 15/697 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/257 | 4/274 | 0/268 | 7/697 |
| Atrial fibrillationCardiac disorders | 0/257 | 1/274 | 1/268 | 8/697 |
| CholelithiasisHepatobiliary disorders | 0/257 | 2/274 | 3/268 | 8/697 |
| Foot deformityMusculoskeletal and connective tissue disorders | 0/257 | 2/274 | 1/268 | 8/697 |
| Myocardial infarctionCardiac disorders | 0/257 | 1/274 | 0/268 | 7/697 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/257 | 0/274 | 0/268 | 7/697 |
| SyncopeNervous system disorders | 2/257 | 0/274 | 1/268 | 7/697 |
| Event | Methotrexate | Adalimumab | Adalimumab + Methotrexate | Any Adalimumab |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 63/257 | 62/274 | 81/268 | 219/697 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 38/257 | 43/274 | 26/268 | 189/697 |
| Upper respiratory tract infectionInfections and infestations | 47/257 | 24/274 | 50/268 | 176/697 |
| HeadacheNervous system disorders | 42/257 | 59/274 | 55/268 | 155/697 |
| HypertensionVascular disorders | 32/257 | 25/274 | 29/268 | 153/697 |
| NauseaGastrointestinal disorders | 53/257 | 48/274 | 46/268 | 131/697 |
| Urinary tract infectionInfections and infestations | 22/257 | 30/274 | 21/268 | 132/697 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 29/257 | 34/274 | 30/268 | 129/697 |
| DiarrhoeaGastrointestinal disorders | 42/257 | 32/274 | 28/268 | 105/697 |
| SinusitisInfections and infestations | 17/257 | 23/274 | 29/268 | 111/697 |
| Age Continuous(years) | Methotrexate | Adalimumab | Adalimumab + Methotrexate | Total |
|---|---|---|---|---|
| Mean | 52.0 ± 13.1 | 52.1 ± 13.5 | 51.9 ± 14.0 | 52.0 ± 13.5 |
| Sex: Female, Male(Participants) | Methotrexate | Adalimumab | Adalimumab + Methotrexate | Total |
|---|---|---|---|---|
| Female | 190 | 212 | 193 | 595 |
| Male | 67 | 62 | 75 | 204 |
Showing the first 100 of 123 sites across 19 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2000, a primary completion of Apr 2004 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 5 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adalimumab · Methotrexate
AbbVie (prior sponsor, Abbott) →